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Abstract 
 
Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide 
that is well-known for its general cytoprotective effects in different neuronal injuries, 
such as traumatic brain and spinal cord injury, models of neurodegenerative diseases, and 
cerebral ischemia. PACAP and its receptors also occur in the retina. In this review, we 
summarize the retinoprotective effects of PACAP. In vitro, PACAP is protective against 
glutamate, thapsigargin, anisomycin, oxidative stress, UV light, high glucose, 
inflammation and anoxia. Both the neural retina and the pigment epithelial cells can be 
protected by PACAP in various experimental paradigms. In vivo, the protective effects of 
intravitreal PACAP treatment have been shown in the following models in rats and mice: 
excitotoxic injury induced by glutamate, N-methyl-D-aspartate (NMDA) or kainate, 
ischemic injury induced by carotid artery ligation and high intraocular pressure, 
degeneration caused by UV-A light, optic nerve transection, and streptozotocin-induced 
diabetic retinopathy as well as retinopathy of prematurity. Molecular biological methods 
have revealed that PACAP activates anti-apoptotic, while inhibits pro-apoptotic signaling 
pathways, and it also stimulates an anti-inflammatory environment in the retina. 
Altogether, PACAP is suggested to be a potential therapeutic retinoprotective agent in 
various retinal diseases. 
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Pituitary adenylate cyclase activating polypeptide (PACAP) 
 
Pituitary adenylate cyclase activating polypeptide (PACAP), was isolated from 
ovine hypothalamus based on its stimulating effect on adenylate cyclase enzyme in 
anterior pituitary cells (Arimura, 2007; Miyata et al. 1989). PACAP has two isoforms; 
PACAP1-27 and PACAP1-38, containing 27 and 38 amino acids, respectively. PACAP is 
a member of the vasoactive intestinal peptide (VIP)/secretin/glucagon superfamily 
(Arimura and Shioda, 1995). Its receptors can be divided into two groups, PAC1 receptor 
and VPAC receptors (VPAC1 and VPAC2) (Vaudry et al. 2009). The biological effects 
of PACAP are diverse (Vaudry et al. 2009), but one of the most studied actions of the 
peptide is its potent neuroprotective effect. Earlier studies have shown that PACAP 
protect neurons in vitro against various toxic agents (glutamate, 6-OHDA, oxidative 
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stress etc.). Neuroprotective role of PACAP has been also demonstrated in vivo in 
different animal models, such as cerebral ischemia, traumatic brain injury, spinal cord 
injury, and Parkinson`s disease. These neuroprotective effects have been summarized in 
several reviews by different authors (Ohtaki et al. 2008; Reglodi et al. 2011, 2015; 
Shioda et al. 2006; Shioda and Nakamachi, 2015; Somogyvari-Vigh and Reglodi 2004; 
Vaudry et al. 2009; Waschek, 2002).  
PACAP is also protective in sensory organs, including the auditory and visual 
systems (Atlasz et al. 2010; Nemeth et al. 2014). The retina is a special tissue, an 
extension of the central nervous system (CNS) containing different neurons, and it also 
provides an excellent model to measure neuronal degenerations. PACAP has been shown 
to protect the different neurons of the retina in numerous in vitro and in vivo models of 
retinal degenerations. The purpose of the present review is to summarize the current 
knowledge of the retinoprotective functions of PACAP. The retinoprotective effects of 
PACAP provide a new, exciting area of research, and several novel data have been 
published since the appearance of the first two extensive reviews on the retinoprotective 
effects of PACAP (Atlasz et al. 2010a; Nakamachi et al. 2012). Therefore, we briefly 
summarize retinoprotective effects until 2010 and discuss findings in the last 5 years 
more in detail.  
 
 
Distribution of PACAP in the retina 
 Several studies have described the presence of PACAP and PACAP receptors in 
the retina in rat. PACAP immunopositive cell bodies were found in amacrine, horizontal 
cells in the inner nuclear layer (INL) in the ganglion cell layer (GCL) and also in the 
Muller glial cells. PACAP positive nerve fibers were also present in the nerve fiber layer 
(NFL), and also in the inner plexiform layer (IPL), but no PACAP positivity was found in 
the outer nuclear layer (ONL) or the retinal pigment epithelium (RPE) layer (D`Agata 
and Cavallaro 1998; Hannibal and Fahrenkrug 2004; Izumi et al. 2000; Kubrusly et al. 
2005; Seki et al. 2000a). The presence of PACAP was also found in the mouse (Mathis 
and Schaeffel, 2007), teleost (Grone et al. 2007), turtle (Reglodi et al. 2001) and chicken 
retina (Jozsa et al. 2001). PACAP appearance showed in a subset of retinal ganglion 
cells, which cells are photosensitive due to expression of melanopsin. The PACAP 
expression in this subset of ganglion cells is partly controlled by dopamine, while it is not 
affected by photoreceptor degeneration (Sakamoto et al. 2005; Wan et al. 2006). 
Melanopsin-containing retinal ganglion cells are known to be more resistant in various 
types of degeneration, such as axonal injury (Perez de Sevilla Muller et al. 2014), and it 
has been proven by numerous studies that these melanopsin-containing cells almost all 
co-store PACAP, which might contribute to the highly resistant nature of these cells 
(Hannibal et al. 2014; La Morgia et al. 2011; Langel et al. 2015). PACAP- and 
melanopsin-containing retinal ganglion cells play an important role in several light-
activated non-image-forming functions of the retina and the complimentary signaling due 
to PACAP neurotransmission has been shown to be important in addition to the 
glutamatergic signaling (Delwig et al. 2013; Purrier et al. 2014).  
PACAP immunopositivity was also found in the limboretinal pathway (Vereczki 
et al. 2006). PACAP and its receptors were also described in the developing retina of 
mammals (Bagnoli et al. 2003) In developing chicken retina PACAP was expressed in 
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the INL from embryonic day 8 (E8) (Borba et al. 2005). In zebrafish during the 
pharyngula period, at 24h of post fertilization PACAP-like immunoreactivity (PACAP-
LI) was detected in the superficial layer of the retina, and during the hatching period, at 
72h of post fertilization in the GCL (Mathieu at al. 2005). PACAP-LI was absent from 
the retina in the zebrafish at day 13 of larval development, suggesting that PACAP may 
have a role in the control of cell differentiation and proliferation (Mathieu at al, 2004, 
2005). In the rat, PACAP mRNA was expressed in the GCL in the developing retina at 
E20 (Skoglosa et al. 1999).   
 
Distribution of PACAP receptors in the retina 
 Earlier studies showed the distribution and localization PACAP receptors in the 
retina. Nilsson et al. (1994) characterized the receptors of PACAP and their coupling to 
adenylate cyclase in albino rat eye, and D`Agata and Cavallaro also described the 
expression of PACAP/VIP receptor variants and their coupling to phospholipase C in the 
rat retina (D`Agata and Cavallaro, 1998). In chicken retina at early stage (E6) PAC1 
receptor and its mRNA can be found (Borba et al. 2005). The mRNA of PACAP 
receptors and the protein expression have also been shown in all the layers of the 
neonatal rat retina (Silveira et al. 2002). Seki et coworkers described the localization and 
strong expression of PAC1 receptor and its mRNA in different retinal layers (NFL, INL, 
GCL), weaker expression in the ONL, OPL, IPL, and the outer segments of the 
photoreceptors in the rat retina (Seki et al. 1997, 2000b). Moreover, different PAC1 
receptor mRNA variants (short, hop) were found in the cell bodies and the processes of 
ganglion and amacrine cells (Seki et al. 1997). Finally, PAC1 receptor has been described 
in Muller glial cells (Kubrusly et al. 2005; Seki et al. 2006). 
PACAP also plays a role in retinal development. The expression of the specific 
PAC1 receptor and VPAC receptors has been confirmed in the developing mammalian 
retina, including the retinal progenitor cells (Njaine et al. 2010). A shift in PAC1 receptor 
isoform expression (null, hip, hop1, hiphop1) during development might explain the 
different roles exerted during differentiation of retinal neural elements (Denes et al. 2014; 
Lakk et al. 2012).  
PACAP controls the proliferation of retinal progenitor cells through the activation 
of all 3 receptors, and the cAMP/PKA/CREB pathway. This activation resulted in 
downregulation of cyclin D1 and the transcription factor Klf4, while p27kip1 protein 
content did not change (Njaine et al. 2010, 2014). The overall effect of these changes was 
an anti-proliferative effect.   
 
 
Protective effects of PACAP in the retina in vitro 
The in vitro protective effects are summarized in Table I. 
 
 In vitro protective effects in the neural retina 
 
The first in vitro studies presented that VIP, a related peptide to PACAP (Shoge et 
al. 1998), or PACAP1-27 and PACAP1-38 (Shoge et al. 1999) have retinoprotective 
effect against glutamate toxicity using cultured retinal neurons. PACAP1-27, PACAP1-
38 and VIP increased cAMP, and the protective effects of VIP or PACAP isoforms were 
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antagonized by VIP6-28 (VIP antagonist) or PACAP6-38 (PACAP antagonist), 
respectively. In addition, H-89 (PKA inhibitor) also decreased the protective effects of 
VIP or PACAP1-27, PACAP1-38.  
 Silveira et al. (2002) found that anisomycin (1µg/ml) inhibits protein synthesis 
and inducing cell death in the neuroblastic layer of retinal explants from newborn rats. 
PACAP1-27 or PACAP1-38 dose-dependently prevented the anisomycin-induced cell 
death. 1nM PACAP1-27 or PACAP1-38 administration in parallel significantly reduced 
the number of dead cells with the terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) procedure and the number of pyknotic profiles per mm2 in the 
neuroblast layer (NBL). A similar retinoprotective effect was observed with PAC1 
receptor agonist maxadilan, but not with glucagon. Neuroprotection by PACAP1-38 was 
also measured in photoreceptor cell death caused by thapsigargin in the ONL (Silveira et 
al. 2002). In the retinal explant model, PACAP6-38 and the specific PAC1 receptor 
antagonist Maxd.4 antagonized the neuroprotective effect. Molecular and 
immunohistochemical analysis demonstrated that the retinoprotective effects are most 
probably mediated by the PAC1 receptor, which is expressed in all the retinal layers of 
the neonatal retina. Treatment of PACAP1-38 induced CREB immunoreactivity in the 
NBL. PACAP1-38 administration also increased cAMP, but not IP3, and a cAMP-
dependent protein kinase inhibitor Rp-cAMPS could block the retinoprotective effects of 
PACAP1-38.  
 In adult turtles, horizontal cells showed light responses 18, 22, 42 and 46 h after 
removal of the eyes. Rabl et al. (2002) demonstrated that the amplitudes of light 
responses were larger in slices at all time-points in PACAP1-38-containing solution 
(0.165 µM PACAP) compared to control retinal slices in anoxic condition. These results 
provide evidence that PACAP1-38 has neuroprotective effects in hypoxic/anoxic 
conditions in the adult turtle retina in vitro. 
 
In vitro protective effects in the retinal pigment epithelial cells 
 
Retinal pigment epithelial (RPE) cells play an essential role in photoreceptor 
survival and metabolism. Several diseases are associated with malfunction of the pigment 
cells. The first results concerning the effects of PACAP came from Zhang et al. (2005). 
Presence of mRNA for PAC1 and VPAC1 receptors was confirmed in unstimulated 
human RPE cells (ARPE19). VPAC2 mRNA was expressed in cells stimulated with IL-
1β. PACAP treatment at 0.1-1 micromolar concentrations inhibited the IL-1 β-stimulated 
IL-6, IL-8, and MCP-1 mRNA and protein levels. The dense immunofluorescence of NF-
κB in the nucleus after stimulation with IL-1β was decreased by PACAP (Zhang et al. 
2005). Studies following these first results in pigment cells revealed several other effects 
of PACAP in these retinal cells. 
ARPE19 cells exposed to PACAP1-38 could be rescued against oxidative stress 
induced by H2O2 in a dose-dependent manner (Mester et al. 2011). Highest efficacy was 
observed at 100 nM PACAP concentration, but it was effective in a range 10 pM-1 µM, 
while not effective at 1 pM. Using flow cytometric and JC-1 assay, PACAP treatment 
was proven to reduce apoptotic cell death. PACAP1-38 and 6-38 alone had no effect on 
cell survival. The survival-promoting effect was inhibited by PI3K/Akt inhibitors, but not 
affected by MAPK inhibitors (Mester et al. 2011). A subsequent study investigated the 
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signaling pathways in oxidative stress-induced pigment epithelial cell damage (Fabian et 
al. 2012). Western blot results revealed that PACAP treatment could activate the 
protective ERK/CREB and Akt pathways, while it inhibited the phosphorylation of p38 
MAPK and JNK. Several cytokines and other apoptotic markers were altered upon 
oxidative stress, as measured by cytokine and phospho-kinase arrays. PACAP 
administration counteracted several of these changes. 10 and 100 nM PACAP decreased 
the oxidative stress-induced increases of the proinflammatory and/or proapoptotic factors 
Bad; Bax; Trail R2 DR5; FADD; Fas TNFR; HIF-1α; HO-1; cIAP-1; HSP-27; 
SMAC/Diablo; p53; eNOS; Paxillin; PLCgamma-1; STAT4; RSK1/2. In contrast, 
PACAP could increase the protective Lyn; Yes; and Src. 
A more recent study has reported that PACAP regulates semaphorin4A 
expression from RPE cells (Ko et al. 2015). The semaphorin protein family has members 
that influence brain and retinal development, by providing neural guidance. 
Semaphorin4A is expressed in the GCL, INL and RPE cell during the developmental 
period of contact-building between photoreceptors and RPE cells. Human ARPE cells 
were co-cultured with PC12 cells (prototype neuronal cells) based on a collagen vitrigel 
membrane. The authors found that in the presence of neural cells the protein and mRNA 
levels of semaphoring4A (but not other semaphorins) were increased, an effect mimicked 
by PACAP (but not VIP, NPY or enkephalin). Furthermore, this effect was also 
associated with ERK phosphorylation (but not that of JNK or p38 MAPK). All these 
effects of PACAP were blocked by the PACAP antagonist PACAP6-38. Furthermore, 
PACAP6-38 downregulated the cytokine IL-6 expression, indicating that endogenous 
PACAP participates in the neural cell-induced IL-6 production (other cytokines out of the 
tested 11 were not influenced by the neuronal co-culture). These results suggest that the 
PACAP secreted by neural cells regulates several factors secreted by RPE cells, 
important for retinal development and homeostasis (Ko et al. 2015). The local secretion 
of PACAP necessary for these effects is supported by the high concentration used in this 
study (1 µM and 10 µM PACAP, lower concentrations were not reported), a 
concentration much higher than the ones reported to exert protective effects against 
oxidative stress (Fabian et al. 2012, Mester et al. 2011). 
Another study investigated the potential of PACAP and VIP against the disruption 
of tight junctions in the retina, a major factor in macular edema developing in diabetic 
retinopathy (Scuderi et al. 2013). ARPE19 cells were cultured either in normal glucose or 
in high glucose in combination with the pro-inflammatory IL-1β. Effects on permeability 
were evaluated by measuring both apical-to-basolateral movements of fluorescein 
isothyocyanate (FITC) dextran and transepithelial electrical resistance (Scuderi et al. 
2013). Results of these experiments demonstrated that normal glucose+IL-1β and, to a 
greater extent, high glucose+IL-1β significantly increased FITC-dextran diffusion, 
paralleled by decreased electrical resistance. PACAP or VIP reversed these effects. 
Furthermore, high glucose+IL-1β-induced reduction of claudin-1 and ZO-1 expression 
was reversed by PACAP and VIP. Occludin expression was not affected in any of the 
conditions tested. Altogether, these finding show that both peptides counteract high 
glucose+IL-1β-induced damage in ARPE19 cells, suggesting that they might be relevant 
to the maintenance of outer blood retinal barrier function in edema accompanying 
diabetic retinopathy (Scuderi et a. 2013). These results are in accordance with our earlier 
observations in an in vitro blood-brain barrier (BBB) model (Wilhelm et al. 2014). We 
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found that PACAP treatment improved the barrier properties of the brain endothelium. 
PACAP induced an increase in the transendothelial electrical resistance, which is the 
most important marker of the tightness of the tight junctions. Moreover, PACAP had a 
protective role against glucose deprivation- and oxidative stress-induced junctional 
damage in microvascular brain endothelial cells (Wilhelm et al. 2014). 
 
 
 
Protective effects of PACAP in the retina in vivo 
The in vivo protective effects are summarized in Table II. 
 
Excitotoxic injury in the retina 
 
 Glutamate, a nonessential amino acid, acts as an excitatory neurotransmitter in the 
retina under normal conditions. However, glutamate in high concentrations can be toxic 
to the retinal cells by overstimulation of the glutamate receptors. Monosodium glutamate 
(MSG) administration given systemically passes the BBB to newborn rats, can injure the 
retina (Szabadfi et al. 2009) and lead to loss of the entire inner retinal layers (Babai et al. 
2006). The excitotoxic damage of the retina is a main factor in retinal diseases, such as 
glaucoma and ischemia-induced retinopathy. We have previously shown in a number of 
studies that PACAP is protective against excitotoxicity induced by systemic 
monosodium-glutamate lesion. We showed that, three times intravitreal MSG treatment 
on postnatal days 1, 5 and 9 caused severe neurodegeneration in the inner retinal layers in 
newborn rat pups (Babai et al. 2005, 2006). Three weeks after the MSG administration 
the thickness of the total retina was decreased, the distance of the outer limiting 
membrane-inner limiting membrane (OLM-ILM) was only half of the normal retina. In 
addition, the IPL almost disappeared, and the fusion of the INL and GCL could be 
observed. The number of the cells per 100µm in the GCL was also decreased (Tamas et 
al. 2004; Babai et al. 2005, 2006; Atlasz et al. 2009a). Although PACAP1-38 is able to 
cross the BBB, systemic PACAP1-38 treatment caused insignificant improvement of the 
retinal morphology following MSG-induced excitotoxic injury (Kiss et al. 2006). In 
contrast, intravitreally injected PACAP1-38 (1-100 pmol) resulted in significant 
amelioration of this degeneration (Babai et al. 2005, 2006; Tamas et al. 2004). While 1 
pmol PACAP1-38 was slightly effective, treatment with 100 pmol PACAP1-38 was able 
to significantly attenuate the MSG-induced toxicity and the entire retina seemed to be 
normal. Similar protection could be seen by PACAP1-27 treatment (Atlasz et al. 2009a). 
The application of the two widely used PACAP antagonists (PACAP6-38, PACAP6-27) 
led to a more pronounced degeneration, indicating that, endogenously present PACAP 
plays a key role against retinal toxicity (Atlasz et al. 2009a). A similar degree of 
retinoprotection was found using enriched environment, but combining these two 
neuroprotective strategies (PACAP and enriched environment) did not result in increased 
neuroprotection in excitotoxic retinal injury (Kiss et al. 2011). 
 Cell-type specific effects of PACAP were shown in MSG-induced retinal 
degeneration by means of immunohistochemistry. In the MSG-treated retinas, the cell 
bodies and processes in the INL, IPL and GCL layers displayed less immunoreactivity for 
vesicular glutamate transporter 1 (VGLUT1), tyrosine hydroxylase (TH), vesicular 
GABA transporter (VGAT), parvalbumin, and calretinin. After MSG treatment the 
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calbindin-positive horizontal cells did not appear to be affected. In MSG+PACAP1-38 
co-treated retinas, the immunoreactivity patterns were similar compared to the normal 
eyes. These data suggest that PACAP has a general, but not subtype-specific protective 
mechanism against glutamate-induced excitotoxic injury in the rat retina (Atlasz et al. 
2008). 
 We also studied potential protective signaling mechanisms in MSG treated 
retinas. We found that intravitreal administration of PACAP preceding the MSG 
treatments induced significant increases in the phosphorylation, that is, the activation of 
ERK1/2 and its downstream target, CREB, 12 h after the treatment compared to the 
contralateral untreated eye during the first two treatments, with no further elevations 24 h 
after treatments. These results demonstrate that the degenerative effect of MSG and the 
protective effect of PACAP involve complex kinase signaling pathways and are related to 
cAMP/ERK/CREB activation (Racz et al. 2006a). Furthermore, after MSG treatment 
proapoptotic signaling proteins such as caspase-3, JNK, apopstosis inducing factor (AIF) 
and cytochrome c increased, and some anti-apoptotic proteins (phospho-PKA, phospho-
Bad, Bcl-xL, 14-3-3) decreased. Co-treatment with PACAP1-38 counteracted the MSG-
induced apoptotic effects, the level of pro-apoptotic signals was significantly decreased, 
while the anti-apoptotic signals proteins were significantly increased (Racz et al. 2006a, 
2006b, 2007). A follow-up study confirmed the anti-apoptotic effect of PACAP in MSG-
induced retinal lesion of the newborns by reinforcing that PACAP decreased caspase-3 
levels and also demonstrating the decreased level of caspase-9 (Lakk et al. 2015). In 
addition, we showed that the PACAP antagonist PACAP6-38 increased cytochrome-C 
release, caspase-3, JNK activity and decreased phospho-Bad, phospho PKA, Bcl-xL, 14-
3-3 activity (Racz et al. 2006b, 2007). These in vivo observations, similarly to the results 
of Atlasz et al. (2009a), indicating that endogenously present PACAP has 
retinoprotective effects in glutamate-induced excitotoxicity. 
 We studied the short-term functional consequences of MSG treatment in the 
mouse retina. Spontaneous and light-evoked spikes of retinal ganglion cells (RGCs) from 
wild type mice were recorded using a 60-channel multielectrode array. MSG remarkably 
elevated the free intracellular calcium (Ca2+) concentration and also increased the 
spontaneous spiking 4-5 minutes after drug application. During this time, spike 
correlations between RGC pairs were reduced. However, after 10-15 minutes of MSG 
application, the spontaneous activity of most RGCs was dramatically reduced or totally 
eliminated. Pretreatment with PACAP1-38 prevented the MSG effects as indicated by 
little or no change in the spontaneous spiking patterns during the course of recordings (up 
to 60 minutes). Moreover, the Ca2+ influx was noticeably decreased by PACAP1-38. In 
addition, MSG blocked the light-evoked responses of all recorded cells. Based on these 
data, application of PACAP1-38, rescued RGCs from the short-term MSG-induced 
insults (Atlasz et al. 2014). 
Kainic acid is a glutamate receptor agonist, which leads to excitotoxic cell death 
in the CNS, including the retina (Seki et al. 2006). It was found that 5 nmol kainic acid 
caused an extensive loss of AMPA/kainate receptors expressing ganglion cells (Zhang et 
al. 1995). Previously we showed that microiontophoretically applied PACAP1-38 could 
block the excitatory effects of kainic acid in several brain areas in vivo (Atlasz et al. 
2006). In the rat retina, pretreatment with 10 pmol intravitreal PACAP1-38, was 
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neuroprotective against kainic-acid induced neurotoxicity, as shown by the attenuated 
ganglion cell loss (Seki et al. 2006).  
N-methyl-D-aspartate (NMDA) treatment also leads to similar lesions. A 
radioimmunoassay analysis showed that in contrast to VIP, retinal PACAP levels do not 
change after intravitreal NMDA injection, which might be caused by a compensatory 
upregulation (Teuchner et al. 2011). A recent study has confirmed that PACAP-mediated 
pathways are protective in NMDA-induced retinal lesion. Cheng et al. (2014) showed 
that intravitreal NMDA injection led to a decrease in light aversion, and decreases in the 
a and b-waves in the electroretinogram accompanied by a photopic negative response. 
These alterations were reversed by cyclic PACAP1-5 treatment. This treatment also 
resulted in decreased ganglion cell loss and apoptosis assessed by TUNEL-staining 
(Cheng et al. 2014). 
 A similar protective effect was described in mice with PACAP1-38, at a 
concentration of 100 pmol.  The PACAP-attenuated NMDA-induced retinal damage in 
mice was associated with modulation of the microglia/macrophage status into an acquired 
deactivation subtype (Wada et al. 2013). NMDA injection led to an increase in 
microglia/macrophage number, while PACAP co-administration attenuated this effect in 
addition to the attenuated ganglion cell loss. The co-administration of the antagonist 
PACAP6-38 counteracted these protective effects and the beneficial effects were not 
observed in IL-10 knockout mice. PACAP administration also led to elevated expression 
of the mRNA for the protective cytokines IL-10 and TGF-β (Wada et al. 2013). In 
summary, these results show that acquired deactivation type of the microglia/macrophage 
cells favors neuroprotection in the retina and this is stimulated by PACAP. 
The question was raised whether these apparent morphological improvements by 
PACAP administration also lead to functional amelioration in MSG-induced retinal 
damage (Varga et al. 2011). Electroretinographic recordings revealed a marked decrease 
in both the b- and a-wave values after MSG treatment, reflecting the function of the inner 
retinal layers and the photoreceptors, respectively. In retinas receiving intravitreal 
PACAP treatment, these values were significantly increased. Thus, the functional 
outcome, although not parallel with the morphology, was significantly improved after 
PACAP treatment. These observations are important from the clinical point of view, 
showing, that PACAP treatment is able to improve the functional properties of the retina 
in excitotoxic damage (Varga et al. 2011). 
 
 
Ischemic injury in the retina 
 
 Retina is one of the most sensitive tissues to hypoxia in the human body. Several 
diseases such as artery occlusion, diabetic retinopathy and high intraocular pressure cause 
hypoperfusion in the retina. Depending on the rat strain, permanent bilateral common 
carotid artery occlusion (BCCAO) leads to reduction in the cerebral blood flow, causes 
hypoperfusion-induced biochemical and behavioral changing and also produces retinal 
degeneration (Atlasz et al. 2007; Mester et al. 2009). Our research group showed in a 
series of experiments that intravitreal PACAP is highly protective in ischemic retinal 
lesion. We found that BCCAO caused severe damage in all layers of the retinas. Two 
weeks after permanent carotid artery ligation, the thickness of the plexiform layers were 
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markedly decreased, and as a consequence, the distance between the OLM-ILM was 
significantly less compared to the control retina. In several treated animals, in the IPL 
some dots of about 1 µm in diameter were seen. Based on the relatively even distribution, 
these dots seemed to be degenerating bipolar cell terminals. In addition, the outer 
segments of the photoreceptors became shorter, and their structure was also damaged 
after the insult (Atlasz et al. 2007). Intravitreal PACAP1-38 treatment following BCCAO 
led to a nearly intact appearance of the retinal layers, which is well reflected by the 
morphometric analysis. The thickness of the all retinal layers, but not the number of cell 
in GCL, was preserved in PACAP1-38 treated animals. PACAP antagonist PACAP6-38 
significantly attenuated the protective effects of PACAP1-38.  
 In 2010, we provided immunohistochemical description of several retinal cell 
types that were damaged by BCCAO and could be partially or fully rescued by 
intravitreal PACAP1-38 treatment. Using the following cell type specific markers 
(VGLUT1, TH, VGAT, parvalbumin, calbindin, calretinin, PKCα, and GFAP) marked 
changes were detected after BCCAO, and the alterations observed in the immunostaining 
for all examined antisera were counteracted by intravitreal PACAP1-38 treatment (Atlasz 
et al. 2010b). These studies provided the basis for the promising therapeutic potential of 
PACAP in ischemic retinal diseases (Szabadfi et al. 2010).   
 Subsequent studies confirmed these original observations. Seki et al. (2011) 
showed that intravitreal PACAP treatment protected ganglion cells against a different 
kind of ischemic lesion induced by high intraocular pressure. In this model, PACAP 
exerted a bimodal protective effect with peaks at 10 fM and 10-1000 pM. The protective 
effect was blocked by cAMP antagonist at both high and low protective doses, while a 
MAP kinase inhibitor only blocked the effects of PACAP at a low dose, suggesting that 
the protective effects of PACAP are mediated by different signaling at low and high 
doses (Seki et al. 2011).  
In a series of studies, we confirmed these findings and compared the efficacy of 
several analogs and related peptides to PACAP1-38 (Szabadfi et al. 2012a; Werling et al. 
2014). We investigated the potential retinoprotective effects of the following PACAP 
fragments: PACAP 4-13, 4-22, 6-10, 6-15, 11-15, and 20-31 and three related peptides 
(VIP, secretin, glucagon) in BCCAO-induced ischemic retinopathy. We confirmed that 
the most effective molecule is PACAP1-38, while the other fragments or related peptides 
did not lead to retinoprotection (Werling et al. 2014). The only exception was VIP, which 
showed retinoprotection in a dose 10 times higher than that of PACAP (Szabadfi et al. 
2012a). In addition, our preliminary results demonstrate that even in form of eye-drops, 
PACAP can lead to retinoprotective effects in ischemic retinopathy, a route of application 
with major possible clinical relevance (Werling et al. 2015).  
In order to elucidate some of the molecular mechanisms, we studied MAP kinases 
and Akt expression as well as cytokines in BCCAO-induced retinal ischemia in rats 
(Szabo et al. 2012). We revealed that PACAP treatment alone did not influence the 
phosphorylation of Akt or the MAPKs, but decreased the hypoperfusion-induced 
activation of both p38MAPK and JNK and increased the activation of the protective Akt 
and ERK1/2 in hypoperfused retinas. The cytokine profile dramatically changed after 
BCCAO, with most cytokines and chemokines (such as CINC, CNTF, fractalkine, 
sICAM, IL-1, LIX, Selectin, MIP-1, RANTES and TIMP-1) increased, a result attenuated 
by PACAP. In addition, PACAP increased the expression of vascular endothelial growth 
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factor (VEGF) and thymus chemokine. These results provided further insight into the 
neuroprotective mechanism induced by PACAP in ischemic retinal injuries, showing that 
PACAP ameliorated hypoperfusion injury involving Akt, MAPK pathways and anti-
inflammatory actions (Szabo et al. 2012). 
Whether the morphological amelioration is accompanied by functional 
improvement was tested using electroretinography (ERG) in another set of experiments 
(Danyadi et al. 2014). Retinal damage and protective effects of PACAP were quantified 
by the changes in the waveforms and amplitudes. BCCAO-induced functional retinal 
degeneration was already observed on postoperative days 2 and lasted throughout the 
entire observation period. Intravitreal injection of PACAP immediately after BCCAO 
resulted in a more retained retinal function as assessed by average ERG waveforms 
compared to the BCCAO-operated groups on both postoperative 2nd and 14th days. ERGs 
of PACAP-treated ischemic eyes were similar to the intact controls in contrast to the 
ERGs of saline-treated BCCAO retinas. PACAP treatment significantly counteracted the 
ischemia-induced alterations in the amplitudes of both the `a` and `b` waves of the ERG 
on postoperative day 14. The elapse time of the five major oscillatory potentials (OPs) 
was reduced in the BCCAO-ischemic group, but PACAP treatment led to significant 
protection. The results confirm that the previously described morphological protection 
induced by PACAP treatment is reflected in functional improvement in ischemic retinal 
lesions (Danyadi et al. 2014). 
 A recent study has revealed several metabolomics changes induced by PACAP in 
ex vivo retinal ischemia induced by sodium azide treatment for various periods of time 
(D’Alessandro et al. 2014). PACAP induced several changes in addition to the reduction 
of ischemia-induced cell death, VEGF overexpression, and glutamate release. Apoptosis, 
as evaluated by TUNEL staining, was reduced in the ONL, INL and GCL. Elevated 
levels of caspase-3 mRNA were also reversed by PACAP treatment. Glutamine, a 
precursor of glutamate, was significantly elevated in ischemic conditions, and reversed 
by PACAP administration. Ischemia is associated with oxidative injury and so the 
authors evaluated the oxidative status of the retinal explants. It was found that PACAP 
had a positive effect on glutathione while it reduced the oxidized glutathione levels, and 
counteracted the increased gamma-glutamyl cysteins levels with accompanying increase 
of cysteine. The accumulation of pro-inflammatory factors and peroxidized lipids was 
prevented by PACAP. Three nitric oxide metabolites were found to be upregulated in 
ischemic retinas: arginine, ornithine and citrulline. Treatment with PACAP reversed these 
changes. The significantly decreased level of cAMP was restored by PACAP treatment 
and glycolytic flues were normalized preventing the over-accumulation of lactate or 
promoting the down-regulation of the glyoxalate antioxidant system. Upregulated inositol 
levels were also abolished. PACAP seemed to promote a shift towards pentose-phosphate 
pathway while maintaining higher levels of NADPH compared to ischemic controls. It 
also led to a down-regulation of purine metabolism. This study concluded that 
peptidergic systems, such as PACAP, deserve attention in treating retinal ischemia 
(D’Alessandro et al. 2014). 
Thanks to all these results, PACAP is now on the list of potential neuroprotective 
molecules in combatting ischemic retinopathy (Cervia and Casini, 2013; Szabadfi et al. 
2010). 
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Optic nerve injury in the retina 
 
Optic nerve transection is a model of apoptotic neuronal cell death in the adult 
CNS (Quigley et al. 1995). Seki et al. (2008) reported that optic nerve trauma resulted 
approximately 55% loss of cells in the GCL. In this model, the number of cells in the 
GCL in animals treated before the operation with PACAP1-38 at 10 and 100 pmol in 3 µl 
saline (dose-dependent) intravitreally, was significantly increased compared with the 
control group on the 14th day after surgery (Seki et al. 2008), providing evidence that 
PACAP is protective in this injury model. 
 
UV radiation injury in the retina 
 
 We showed, for the first time, that PACAP protected against in two different 
kinds (diffused and focused) of ultraviolet (UV)-A induced degenerations. Thickness of 
all layers as well as the number of cells in the ONL and INL and in the GCL was 
evaluated by standard morphological and morphometrical analyses. After diffuse UV-A 
irradiation, significant decrease of the number of the cells in the GCL was observed. In 
addition, severe degeneration in the ONL and INL was seen, and the IPL was swollen. 
PACAP1-38 treatment after the UV-A irradiation significantly ameliorated the light-
induced degeneration, the ONL and INL thickness seemed to be normal, and the number 
of cells in INL, ONL and GCL was significantly increased (Atlasz et al. 2011). In a 
model of focused UV-A irradiation, the shape of the laser focus was observed on the 
retina, tissue gaps were found in the ONL and in the photoreceptor layer, and the IPL was 
reduced. The total thickness of the retina was significantly less than in unaffected areas. 
We observed protective effects of PACAP in all of the different retinal layers (Atlasz et 
al. 2009b).  
 Succeeding studies confirmed this effect in several different models. In an in vitro 
model of UV-B irradiation, PACAP was shown to protect RGC-5 retinal ganglion cells 
expressing PAC1 receptors (Cheng et al. 2014; Ding et al. 2012). This effect was 
mimicked also by a cyclic PACAP derivative, cyclic PACAP1-5 (Cheng et al. 2014). 
Furthermore, pretreatment with this short derivative effectively blocked apoptosis, 
maintained structural integrity, decreased production of reactive oxygen species (ROS). 
Both PACAP and cyclic PACAP1-5 counteracted the UV-B-induced decrease in the 
protective bcl-2 and the increase in the deleterious bax protein levels (Cheng et al. 2014). 
 
Diabetic retinopathy in the retina 
 
Our recent studies have shown that PACAP is also protective in diabetic 
retinopathy, a major microangiopathy affecting the vision of diabetic patients. Our first 
results demonstrated that in the early stages of diabetic retinopathy, amacrine cells 
underwent characteristic degeneration, especially the dopaminergic amacrine cells. 
PACAP prevented the typical alterations induced in 1-month diabetes: the degeneration 
in arborization and synapses of tyrosin-hydroxylase positive dopaminergic amacrine cells 
(Atlasz et al. 2010b). In a rat model of streptozotocin-induced diabetic retinopathy (DR), 
early signs do not include overall changes in thickness of retinal layers, but the decrease 
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in the number of ganglion cells and the upregulation of GFAP as a sign of Müller glial 
cell activation, can be observed. These changes were counteracted by 3 times 100 
pmol/5µl intravitreal PACAP administration (Szabadfi et al. 2012b). Furthermore, the 
degeneration of the photoreceptor outer segments and terminals was attenuated in 
PACAP-treated rats. PACAP increased the levels of PAC1-receptor and TH determined 
with molecular biological methods. These early results suggested a therapeutic potential 
in DR.  
Subsequently, our research group and others confirmed these early findings 
(Szabadfi et al. 2014a). Intraocular PACAP injection markedly attenuated diabetic retinal 
injury: increased levels of the anti-apoptotic p-Akt, p-ERK1, p-ERK2, PKC, Bcl-2, while 
decreased levels of the pro-apoptotic p-p38MAPK and activated caspases (8, 3, 12) were 
detected. The number of apoptotic cells increased in all nuclear layers of diabetic retinas, 
but significantly decreased after PACAP treatment. Our results clearly demonstrated that 
the protective effects of PACAP are mediated, at least partly, by attenuating apoptosis, 
including also that of the dopaminergic amacrine cells (Szabadfi et al. 2014a). Our most 
recent study shed further light on this PACAP-induced retinoprotection. Electron 
microscopic analysis revealed that retinal pigment epithelium, the ribbon synapses and 
other synaptic profiles suffered alterations in diabetes. However, in PACAP-treated 
diabetic retinas more bipolar ribbon synapses were found intact in the inner plexiform 
layer than in DR animals. The ribbon synapse was marked with C-terminal binding 
protein 2 (CtBP2)/Bassoon and formed horseshoe-shape ribbons, which were more 
retained in PACAP-treated diabetic retinas than in DR rats. These results are supported 
by molecular biological data. The selective degeneration of related structures such as 
bipolar and ganglion cells could be ameliorated by PACAP treatment. In summary, 
intravitreal administration of PACAP may have therapeutic potential in streptozotocin-
induced DR through maintaining synapse integrity in the vertical pathway (Szabadfi et al. 
2016). 
D’Amico and coworkers (2015) analyzed the expression of hypoxia-induced 
factors (HIF) in DR 3 weeks after the induction of diabetes with streptozotocin. They 
found that the expression of HIF-1α and HIF-2α significantly increased in diabetic rats, 
but not after 1 intravitreal PACAP treatment. Conversely, the expression of HIF-3α was 
significantly downregulated in retinas of diabetic rats, and increased after PACAP 
treatment. These results suggest that the retinoprotective effects of PACAP are partially 
mediated by interfering with the expression of HIFs that play an important role in 
pathological vasculogenesis occurring in DR (D’Amico et al. 2015). 
These studies, together with the results demonstrating the effects of PACAP on 
the blood-retinal barrier properties in vitro (see above), show that PACAP has therapeutic 
potential in diabetic retinopathy (Gabriel 2013; Marzagalli et al. 2015; Szabadfi et al. 
2014b). Several experimental evidence support the efficacy of PACAP treatment in 
animal model of diabetes-related diseases, such as diabetic nephropathy, another major 
microangiopathic complication of diabetes (Banki et al. 2013, 2014). Thus, PACAP is 
among the emerging molecules to fight diabetic complications, similarly to VEGF 
antagonists, antioxidants, anti-inflammaotry agenst and other neuropeptides (Gabriel 
2013; Ola et al. 2015; Scuderi et al. 2015).  
 
Retinopathy of prematurity (ROP) 
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ROP is a major complication in premature newborns. It is a vasoproliferative disorder, 
the main features of which are well depicted in a rat model of oxygen-induced 
retinopathy. Our preliminary studies have shown that PACAP is able to reverse some of 
the deleterious effects of this retinopathy. Intravitreal PACAP1-38 treatment ameliorated 
the vascular extent of the retinopathic eyes without alterations in vessel morphology. 
Moreover, cytokine expression profiles indicate that PACAP may block the new vessel 
formation and have a positive influence on the remodeling of the tissue (Kvarik et al. 
2015). 
 
 
Studies in PACAP and receptor gene modified animals 
 
We have described that although PACAP deficient mice have normal retinas at 
young age, aging signs appear earlier than in their wild-type mates (Szabadfi et al. 
2012c). As it has been shown in numerous models, PACAP knockout (KO) mice are 
more vulnerable to different types of tissue injuries from ischemia to oxidative stress and 
even trauma (Reglodi et al. 2012). In our experiments, PACAP KO mice that underwent 
10 min of BCCAO followed by 2-week reperfusion period had significantly greater 
retinal damage, as shown by the thickness of the whole retina, the morphometric analysis 
of the individual retinal layers, and the cell numbers in the inner nuclear and ganglion cell 
layers. Exogenous PACAP administration could partially protect against this retinal 
degeneration in the KO mice. These results clearly show that endogenous PACAP reacts 
as a stress-response peptide that is necessary for endogenous protection against different 
retinal insults (Szabadfi et al. 2012d).  
The higher vulnerability of PACAP deficient mice against lesions was confirmed 
by another study by Endo et al. (2011). The authors found, in accordance with our results, 
that under normal circumstances, there was no difference in the number of retinal 
ganglion cells in heterozygous PACAP deficient mice and wild-type counterparts (Endo 
et al. 2011). However, when these mice were subjected to NMDA-induced toxicity, 
PACAP heterozygous mice reacted with increased loss of ganglion cells (Endo et al. 
2011). The number of apoptotic cells, as measured by TUNEL staining, peaked on day 1 
in heterozygous mice, while the peak was on day 3 in wild-types, suggesting that 
apoptotic cell death began earlier in mice deficient in PACAP. These effects were 
reversed by simultaneous injection of PACAP in heterozygous mice. These results 
confirm that endogenous PACAP is protective in the retina and prove that even partial 
loss of PACAP-driven neuroprotection decreases resistance against harmful effects (Endo 
et al. 2011). Our recent, preliminary results also confirm that endogenous PACAP is 
protective in lipopolysaccharide (LPS)-induced retinal inflammation, as shown by the 
increased inflammatory status of PACAP KO. Twenty-four hours after LPS treatment 
several cytokines and chemokines showed significant increase in the PACAP knockout 
mice compared to the normal, wild types (Atlasz et al. 2015).  
Little is known about retinal morphology or function in mice with PAC1 receptor 
abnormalities. Engelund and coworkers (2012) described that pupillary light reflex was 
altered in PAC1 receptor knockout mice. The finding that PACAPergic signaling is 
essential for normal retinal development is also confirmed by studies with transgenic 
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mice. It was described by Lang et al. (2010) during development that overexpression of 
the PAC1 receptor led to an early exit from retinal proliferation, reduced signaling of 
GABAergic neurons. Furthermore, this led to decreased visual function (Lang et al. 
2010). These data show that a proper balance of PACAP signaling is required for 
appropriate retinogenesis and visual acuity. 
 
 
Studies in tumor cells 
 
PACAP can exert different effects in cells derived from various sources and especially 
from tumors. While in most cell types PACAP is protective, in some tumors it exerts 
toxic effects (Brubel et al. 2010). Furthermore, PACAP6-38 is in most cell types an 
antagonist, it can also behave as an agonist in some, tumorous and even non-tumorous, 
cells (Juhasz et al. 2015, Saghy et al. 2015). Retinoblastoma is a malignant tumor of 
retinal progenitor cells. Human retinoblastoma cells are known to express PACAP 
receptors (Olianas et al. 1996). In Y79 retinoblastoma cells, PACAP1-38 did not 
influence cell survival at nanomolar concentrations, but at 1-5 micromolar 
concentrations, it reduced survival (Wojcieszak and Zawilska, 2014). Interestingly, 
PACAP1-27 and maxadilan had negligible effects, while two membrane-penetrating 
analogs of PACAP also decreased cell viability. The authors also revealed that this 
cytotoxic effect might be via an interaction of p38, MEK1/2 and JNK signaling, because 
inhibitors of these pathways led to an even more expressed cytotoxicity (Wojcieszak and 
Zawilska, 2014). These results suggest that high concentrations of PACAP1-38 might 
lead to a transmembrane penetration and lead to direct cytotoxicity at sites other than the 
conventional PACAP receptor-mediated signaling.  
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Abbreviations: 
 
 
6-OHDA: 6-hydroxydopamine 
AIF: apopstosis inducing factor 
AMPA receptor: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
Bad: Bcl-2-associated death promoter 
Bax: Bcl-2-associated X protein 
BBB: blood-brain barrier 
BCCAO: bilateral common carotid artery occlusion 
Bcl-2: B-cell lymphoma 2 
Bcl-xl: B-cell lymphoma-extra large 
cAMP/PKA/CREB: ciklikus AMP/protein-kina A/ cAMP response element-binding 
protein  
CIAP-1: cellular inhibitor of apoptosis protein-1 
CINC: cytokine-induced neutrophil chemoattractant 
CNS: central nervous system 
CNS: central nervous system 
CNTF: ciliary neurotrophic factor 
CtBP2: C-terminal binding protein 2 
DR: diabetic retinopathy 
eNOS: endothelial nitric oxide synthase 
ERG: electroretinography 
ERK: extracellular-signal-regulated kinase 
Fas TNFR: Fas tumor necrosis factor  receptor 
FITC: fluorescein isothyocyanate 
GCL: ganglion cell layer. 
GFAP: glial fibrillary acidic protein 
HIF1α,2α,3α: hypoxia-inducible factor 1-alpha, 2-alpha, 3-alpha 
HO-1: heme oxygenase 1 
HSP-27: heat shock protein 27 
IL-1β: interleukin-1 beta 
INL: inner nuclear layer 
IP3: inositol trisphosphate 
IPL: inner plexiform layer 
JNK: c-Jun N-terminal kinase 
LPS: lipopolysaccharide 
MAPK: mitogen-activated protein kinase 
MIP-1: macrophage inflammatory protein 1 
MSG: monosodium glutamate 
NBL: neuroblast layer  
NF-κB: nuclear factor-κB 
NFL: nerve fiber layer 
NMDA: N-methyl-D-aspartate 
NPY: neuropeptide Y 
OLM-ILM: outer limiting membrane-inner limiting membrane 
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ONL: outer nuclear layer 
OPL: outer plexiform layer 
Ops: oscillatory potentials 
PAC1: PACAP receptor 1 
PACAP KO: PACAP knockout 
PACAP: adenylate cyclase activating polypeptide 
PKCα: protein kinase C alpha 
PLCgamma-1: phospholipase C gamma-1 
RANTES: regulated on activation, normal T cell expressed and secreted 
RGCs: retinal ganglion cells  
ROP: retinopathy of prematurity 
ROS: reactive oxygen species 
RPE: retinal pigment epithelial  
RPE: retinal pigment epithelium 
RSK1/2: ribosomal s6 kinase 1,2 
sICAM: soluble intercellular adhesion molecule  
STAT4: signal transducer and activator of transcription 4 
TH: tyrosine hydroxylase 
TIMP-1: tissue inhibitor metallopeptidase inhibitor 1 
Trail R2 DR5: TRAIL receptor 2 - death receptor 5  
TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling 
TGF-β : transforming growth factor beta 
UV-A, B: ultraviolet A, ultraviolet B 
VEGF: vascular endothelial growth factor 
VGAT: vesicular GABA transporter 
VGLUT1: vesicular glutamate transporter 1 
VIP: vasoactive intestinal peptide  
VPAC1: vasoactive intestinal peptide (VIP) receptor type 1 
VPAC2 (vasoactive intestinal peptide (VIP) receptor type 2 
ZO-1: zona occuldens protein 1 
